NeoGenomics Unveils Study Showing Advanced Genomic Profiling Improves Myeloid Cancer Diagnosis

Reuters

2025/12/08

<a href="https://laohu8.com/S/NEO">NeoGenomics</a> Unveils Study Showing Advanced Genomic Profiling Improves Myeloid Cancer Diagnosis

NeoGenomics Inc. has announced that it will present new data from a real-world study on comprehensive genomic profiling (CGP) in myeloid malignancies at the 67th American Society of Hematology $(ASH)$ Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The study evaluates the Neo Comprehensive Myeloid panel, a next-generation sequencing assay designed to provide a comprehensive assessment of genomic changes in myeloid cancers. The poster, titled "Comprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies: A real-world analysis," will be presented on December 8. The data highlights the ability of the CGP panel to detect important genomic variants, supporting diagnosis, prognosis, and therapy selection for acute myeloid leukemia, myelodysplastic neoplasms, and myeloproliferative neoplasms. Results of the study will be presented at the upcoming conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208548164) on December 08, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2589353678"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2589353678\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2589353678?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589353678","market":"fut","top_or_hot":-1,"title":"NeoGenomics Unveils Study Showing Advanced Genomic Profiling Improves Myeloid Cancer Diagnosis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NEO\">NeoGenomics</a> Unveils Study Showing Advanced Genomic Profiling Improves Myeloid Cancer Diagnosis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeoGenomics Inc. has announced that it will present new data from a real-world study on comprehensive genomic profiling (CGP) in myeloid malignancies at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The study evaluates the Neo Comprehensive Myeloid panel, a next-generation sequencing assay designed to provide a comprehensive assessment of genomic changes in myeloid cancers. The poster, titled \"Comprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies: A real-world analysis,\" will be presented on December 8. The data highlights the ability of the CGP panel to detect important genomic variants, supporting diagnosis, prognosis, and therapy selection for acute myeloid leukemia, myelodysplastic neoplasms, and myeloproliferative neoplasms. Results of the study will be presented at the upcoming conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208548164) on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeoGenomics Unveils Study Showing Advanced Genomic Profiling Improves Myeloid Cancer Diagnosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeoGenomics Unveils Study Showing Advanced Genomic Profiling Improves Myeloid Cancer Diagnosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NEO\">NeoGenomics</a> Unveils Study Showing Advanced Genomic Profiling Improves Myeloid Cancer Diagnosis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeoGenomics Inc. has announced that it will present new data from a real-world study on comprehensive genomic profiling (CGP) in myeloid malignancies at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The study evaluates the Neo Comprehensive Myeloid panel, a next-generation sequencing assay designed to provide a comprehensive assessment of genomic changes in myeloid cancers. The poster, titled \"Comprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies: A real-world analysis,\" will be presented on December 8. The data highlights the ability of the CGP panel to detect important genomic variants, supporting diagnosis, prognosis, and therapy selection for acute myeloid leukemia, myelodysplastic neoplasms, and myeloproliferative neoplasms. Results of the study will be presented at the upcoming conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208548164) on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0012050646.USD","symbol_name":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDLbS6NtM:1","article_id":"2589353678","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589353678","pubTimestamp":1765199122,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NeoGenomics Inc. has announced that it will present new data from a real-world study on comprehensive genomic profiling  in myeloid malignancies at the 67th American Society of Hematology  Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The study evaluates the Neo Comprehensive Myeloid panel, a next-generation sequencing assay designed to provide a comprehensive assessment of genomic changes in myeloid cancers. The poster, titled \"Comprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies: A real-world analysis,\" will be presented on December 8. The data highlights the ability of the CGP panel to detect important genomic variants, supporting diagnosis, prognosis, and therapy selection for acute myeloid leukemia, myelodysplastic neoplasms, and myeloproliferative neoplasms. Results of the study will be presented at the upcoming conference.Disclaimer: This news brief was created by Public Technologies  using generative a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","BK4121":"生命科学工具和服务","NEO":"NeoGenomics","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","BK4196":"保健护理服务"},"translate_title":"NeoGenomics公布的研究显示先进的基因组图谱可改善骨髓癌诊断","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEO":0.9},"content_text":"NeoGenomics Unveils Study Showing Advanced Genomic Profiling Improves Myeloid Cancer Diagnosis\n    \n\n        NeoGenomics Inc. has announced that it will present new data from a real-world study on comprehensive genomic profiling (CGP) in myeloid malignancies at the 67th American Society of Hematology $(ASH)$ Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The study evaluates the Neo Comprehensive Myeloid panel, a next-generation sequencing assay designed to provide a comprehensive assessment of genomic changes in myeloid cancers. The poster, titled \"Comprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies: A real-world analysis,\" will be presented on December 8. The data highlights the ability of the CGP panel to detect important genomic variants, supporting diagnosis, prognosis, and therapy selection for acute myeloid leukemia, myelodysplastic neoplasms, and myeloproliferative neoplasms. Results of the study will be presented at the upcoming conference.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208548164) on December 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}